Reposted by Erika Hamilton MD, FASCO
Adding the TKI inhibitor tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab prolonged PFS among patients with HER2-positive metastatic #breastcancer. Presented at @sabcs.bsky.social #SABCS25 by @erikahamilton9.bsky.social of @scri.com.
bit.ly/3XOkT4M
#bcsm